ANZCTR Data Dictionary

This document is a data dictionary for fields that are available for download in the ANZCTR. For a complete list of definitions and explanations of all data fields completed when submitted a record for registration on the ANZCTR, please use the data field definition document available here on the ANZCTR website.

Table1: Trial tab

Tab name: TRIAL **Description:** Characteristics of the trials			
Variable name	Description	Values	Notes
Trial ID	Unique trial ID, also known as the request number (Note: this is different to the registration number (ACTRN))	Integer	
ACTRN	Registration number	ACTRN followed by a 12-digit number	Some ACTRN have a 'p' on the end, indicating provisional registration. This means that the study has not yet received ethics approval.
SUBMIT DATE	Date of submission	dd/mm/yyyy hh:mm:sec	
APPROVAL DATE	Data of registration	dd/mm/yyyy hh:mm:sec	
STUDY TITLE	Study title	String	The public title of the study is intended for the lay public and should be in easily understood language.
SCIENTIFIC TITLE	Scientific Title	String	The scientific title is intended for use in grant and ethics applications. It also includes the participant group, intervention, and primary outcome.
UTN	Universal trial number	String	The Universal Trial Number (UTN) is a unique number which aims to facilitate the unambiguous identification of clinical trials

			registered in Primary Registries in the WHO Registry Network and displayed on the WHO ICTRP Search Portal
TRIAL ACRONYM	Trial acronym	String	A trial acronym is a word formed from the initial letters of the several words in the name, which identifies the specific trial, e.g. ACT (Angioplasty Compliance Trial)
LINKED STUDY	Identifying number of a parent study, sub-study or follow-up study	String	
INTERVENTIONS	Description of the specific intervention(s) being studied.	Free Text	
COMPARATOR	Description of comparator	Free text	The comparator/control(s) is/are the treatments against which the study intervention is being compared (e.g. placebo, no treatment, active control).
CONTROL	Type of Control	Active Uncontrolled Placebo Historical Dose comparison	A "control" group is the type of treatment to which the intervention is being compared, also known as a "comparator" group. **Placebo**: an inactive or sham treatment that has no treatment value is given to the control group, such as sugar pill or saline solution. **Active**: when the control treatment is active. This includes standard care, alternate forms of treatment, no treatment given, or if patients act as their own control (crossover study). **Uncontrolled**: when there is no control group, as in single group trials. The same intervention is applied to all subjects in the

			study. Historical: a group of people who received their care in the past, i.e. not at the same time as the people receiving the intervention. This selection is not applicable for randomised controlled trials. The source and time period that historical data was collected needs to be described in the 'Comparator / control treatment' field. **Dose comparison**: the comparator group receives the same treatment as the intervention group, but in a different dose. Note: Only 1 selection is allowed per record
INCLUSIVE CRITERIA	Inclusion criteria	String	Summary of key inclusion criteria of patient characteristics that determine eligibility for participation in the study.
MIN AGE	Minimum age of eligible study participants	Numeric	Not available means there was no age limit in the study
MIN AGE TYPE	The format that minimum age has been recorded in	Year Months Weeks, Days Hours No limit Not stated	"Not stated" is no longer available and it only belongs to older records
MAX AGE	Maximum age of eligible study participants	Numeric	Not available means there was no age limit in the study
MAX AGE TYPE	The format that maximum age has been recorded in	Year Months Weeks, Days Hours	"Not stated" is no longer available and it only belongs to older records

		No limit Not stated	
INCLUSIVE GENDER	Sex of study participants	Both males and females Males Females	
HEALTHY VOLUNTEERS?	Indicate whether healthy volunteers may participate in this study	Yes No	Studies where the Inclusion Criteria requires pregnant women or those with any condition, including non-debilitating conditions (e.g. myopia, smoking, etc.), are not considered healthy volunteer studies and they have been recorded as “No”.
EXCLUSIVE CRITERIA	Exclusion criteria	String	Summary of key exclusion criteria of patient characteristics that determine eligibility for participation in the study
STUDY TYPE	Study type	Interventional Observational	**Interventional:** Any research study that prospectively assigns human participants or groups of humans to one or more health related interventions to evaluate the effect on outcomes. **Observational:** A study in which no experimental intervention or treatment is applied. It involves observing without altering or influencing that which is being observed.
PURPOSE	Purpose of the study	Treatment Educational/ counselling/ training Diagnosis Prevention	**Note:** Only one selection is allowed per record

ALLOCATION	appropriate type of allocation to intervention	Randomised controlled trial Non-randomised trials	**Randomised controlled trial** means that allocation of subjects into different groups was random or by a method based on chance. **Non-randomised trial** means that allocation of subjects into different groups is expressly or deliberately done, and is not random or by chance. **Note**: Trials with quasi-randomisation allocation procedures do not qualify as a randomised trial.
CONCEALMENT	Allocation concealment	String	**Allocation concealment** means that the person who determined if a subject was eligible for inclusion in the trial was unaware, when this decision was made, to which group the subject would be allocated. **Note**: Only applicable for randomised controlled trials.
SEQUENCE	This is the method used to create the random order for the allocation of subjects into different groups	String	Quasi-randomisation allocation procedures or inappropriate randomisation methods such as allocation by hospital record number, birth date or alternate days of the week, do not qualify as a random order generation
MASKING	Masking / blinding is when the person in question (participant, therapist/clinician, assessor or data analyst) did not know which group the	Blinded (masking used) Open (masking not used)	For trials in which key outcomes are self-reported (e.g. visual analogue scale, pain diary), the assessor is considered to be blinded if the subject was blinded. **Note**: 1. Only applicable for randomised controlled trials.

	participant had been allocated to		2. Only available when Interventional is selected for study type.
ASSIGNMENT	The most appropriate description of the study's assignment	Single group Parallel Crossover Factorial Other	**Single group**: all participants receive the same intervention throughout the study. **Parallel:** different groups of participants receive different interventions during the same time span of the study. **Crossover**: all participants receive all the interventions in random order or in a specific sequence (non-randomised) during the study. They act as their own control. **Factorial**: participants are randomly allocated to receive either no intervention, one or some interventions, or all interventions combined. **Other**: None of the selections provide an appropriate description of the study's assignment **Note:** Only available when Interventional is selected for study type
OTHER DESIGN FEATURES	Other comments about the design of the study	String	**Note:** Only available when Interventional is selected for study type
ENDPOINT	The most appropriate study endpoint(s)	Safety Efficacy Safety/efficacy Bio-equivalence Bio-availability Pharmacokinetics Pharmacodynamics	**Safety**: to show if the intervention is safe under conditions of proposed protocol/use. **Efficacy**: to measure an intervention's influence on a disease or health condition. **Safety/efficacy**: combination of safety and efficacy. **Bio-equivalence**: scientific basis for comparing generic and brand name drugs.

			Bio-availability: rate and extent to which a drug is absorbed or otherwise available to the treatment site in the body. **Pharmacokinetics**: the action of a drug in the body over a period of time including the process of absorption, distribution and localisation in tissue, biotransformation, and excretion of the compound. **Pharmacodynamics**: action of drugs in living systems. **Note:** Only available when Interventional is selected for study type
PHASE	The trial phase.	Phase 0 Phase 1 Phase 1/Phase 2 Phase 2 Phase 2/Phase 3 Phase 3 Phase 3/Phase 4 Phase 4 Not applicable	**Phase 0**: includes exploratory, first-in-human trials. **Phase 1**: includes initial study to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. **Phase 1/Phase 2**: for trials at a combined stage of phases 1 and 2. **Phase 2**: includes controlled clinical studies conducted to evaluate/test the effectiveness of a new drug/medication or intervention for a particular indication or indications in patients with the disease or condition being studied and to determine the common short-term side effects and risks. **Phase 2/Phase 3**: for trials at a combined stage of phases 2 and 3.

			Phase 3: includes expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of a new drug/medication or intervention, including possible adverse reactions. **Phase 3/Phase 4**: for trials at a combined stage of phases 3 and 4. **Phase 4:** post-marketing study to delineate additional information. **Not applicable**: this selection is for a non-drug trial. **Note:** 1. Phases of investigation generally only apply to drug trials for the purposes of registration. 2. Only available when Interventional is selected for study type
STATISTICAL METHODS	A brief summary of the statistical methods and/or analysis plan to be used to evaluate the data.	String	
MASKING1(PARTICIPANTS)	Indicates if the participants were blinded	TRUE FALSE	
MASKING2(CLINICIAN/THERAPIST)	Indicates if the clinicians/ therapists were blinded	TRUE FALSE	
MASKING3(OUTCOMES ASSESORS)	Indicates if the outcomes assessors were blinded	TRUE FALSE	
MASKING4(DATA ANALYST)	Indicates if the data analysts were blinded	TRUE FALSE	

PATIENT REGISTRY?	Indicates if this record describes a study that is considered to be a patient registry.	TRUE FALSE	A patient registry is an organised system that uses observational methods to collect uniform data prospectively for a population defined by a particular disorder/disease, condition, or exposure and that serves a predetermined scientific, clinical, or policy purpose. **Note:** Only available when Observational is selected for study type
REGISTRY FOLLOW-UP	For patient registries, the anticipated time period over which each participant is to be followed.	Numeric	Only applicable if TRUE selected for 'PATIENT REGISTRY' field above.
REGISTRY FOLLOW-UP TYPE	For patient registries, the type of anticipated time period over which each participant is to be followed.	Weeks Months Years	Only applicable if TRUE selected for 'PATIENT REGISTRY' field above.
PURPOSE(OBSERVATIONAL)	Purpose of the study	String	**Natural history**: study designed to investigate a disease or condition through observation under natural conditions (i.e. without intervention), **Screening**: study designed to assess or examine persons or groups in a systematic way to identify specific markers or characteristics (e.g. for eligibility for further evaluation). **Psychosocial**: study designed to observe the psychosocial impact of natural events. **Note:** Only available when Observational is selected for study type

DURATION(OBSERVATIONAL)	Duration of the study	Numeric	**Note:** Only available when Observational is selected for study type
SELECTION(OBSERVATIONAL)	Sample selection of the study	Convenience sample Defined population Random sample Case control	**Convenience sample**: participants or populations are selected at the convenience of the investigator or primarily because they were available at a convenient time or place. **Defined population:** participants or populations are selected based on predefined criteria. **Random sample:** participants or populations are selected by chance in a manner such that all samples of a population have an equal chance of being selected. **Case control:** participants or populations are selected to match control participants or populations in all relevant factors except for the disease; only the case participants or populations have the disease. **Note:** Only available when Observational is selected for study type
TIMING(OBSERVATIONAL)	Timing of the study	Retrospective Prospective Both	**Retrospective:** study that observes events in the past. **Prospective:** study that observes events in real time (may also occur in future). **Both:** study that combines retrospective and prospective observation. **Note:** Only available when Observational is selected for study type
ANTICIPATED START DATE	Anticipated date of randomisation of the first participant for randomised	dd/mm/yyyy	

	trials. For non-randomised studies, it is defined as anticipated date that the first participant commences treatment/intervention/exposure		
ACTUAL START DATE	Actual date of randomisation of the first participant for randomised trials. For non-randomised studies, it is defined as the actual date that the first participant commences	dd/mm/yyyy	
ANTICIPATED END DATE	Anticipated date that recruitment into the study will cease.	dd/mm/yyyy	
ACTUAL END DATE	Actual date that the final participant was enrolled into the study	dd/mm/yyyy	
TARGET SAMPLE SIZE	The total number of participants the investigators plan to enrol before closing the trial to new participants.	Numeric	
FINAL SAMPLE SIZE	The final number of participants enrolled into the study at close of recruitment.	Numeric	
CURRENT SAMPLE SIZE	The total number of participants who have been enrolled into the study to date.	Numeric	

ANTICIPATED LAST VISIT DATE	Anticipated date of last data collection for last participant.	dd/mm/yyyy	
ACTUAL LAST VISIT DATE	Actual date that last data was collected for the last participant.	dd/mm/yyyy	
RECUITMENT STATUS	The study's current recruitment status	Not yet recruiting Recruiting Active, not recruiting Completed Withdrawn Suspended Stopped early	**Not yet recruiting:** participants are not yet being recruited **Recruiting:** open for recruitment and the first participant has been enrolled **Active, not recruiting:** closed to recruitment and participants are being treated or examined **Completed:** the study has concluded normally; participants are no longer being treated or examined (i.e. follow-up and data collection are complete) **Withdrawn:** study halted prematurely, prior to enrolment of first participant **Suspended:** there is a temporary halt in recruitment and enrolment but potentially will resume **Stopped early:** recruiting or enrolling participants has halted prematurely and will not resume
DATA ANALYSIS	Data analysis status	No data analysis planned Data collected is being analysed Data analysis is complete	This variable is only available when **Stopped early** is selected for 'Recruitment status'

WITHDRAWN REASON	Reason for early stopping/ withdrawal	Lack of funding/staff/facilities Participant recruitment difficulties Safety concerns Other reasons/comments(plea se specify)	This variable is only available when **Withdrawn** or **Stopped early** is selected for Recruitment status
WITHDRAWN REASON(OTHER)	Reason for early stopping/ withdrawal	String	It is only available if, Other reasons/comments is selected in the withdrawn reason field
RECRUITMENT COUNTRY	Indicate where recruitment occurred	Australia Outside Australia, outside	
RECRUITMENT STATE	Indicate in which state of Australia did the recruitment occurred	NSW VIC QLD ACT NT TAS WA	Trials may include any combination of States and territories
PRIMARY SPONSOR	Specifies the type of primary sponsor	Government body Hospital University Commercial sector/industry Charities/societies/found ations Other collaborative groups	The individual, organisation, group or other legal person taking on responsibility for securing the arrangements to initiate and/or manage a study, including arrangements to ensure that the design of the study meets appropriate standards and to ensure appropriate conduct and reporting.

		Individual Other	
PRIMARY SPONSOR NAME	Name of the study's primary sponsor.	String	
PRIMARY SPONSOR COUNTRY	Country of primary sponsor	String	
ETHICS STATUS	Ethics application status	Not yet submitted Submitted, not yet approved Approved Not required	
BRIEF SUMMARY	Short description of the primary purpose of the study	String	This includes a brief statement of the study hypothesis, intended for the lay public.
TRIAL WEBSITE	Web address/ URL of the trial (if applicable)	String	
PUBLICATION	Trial related presentations / publication	String	This is a legacy field which was replaced the SUPPORTING DOCUMENTS and STUDY RESULTS tab in October 2018.
PUBLIC NOTES	Miscellaneous text that trialist would like included within the trial registration record which is not relevant elsewhere on this form	String	

Table2: Secondary ID tab

Tab name: SECONDARY ID **Description:** Information on secondary ID **Note:** Studies may include more than one secondary ID			
Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
Secondary ID	Identifying numbers issued by authorities other than the ANZCTR if any. Such as WHO, sponsors, funding bodies, etc.	String	All secondary identifiers will have 2 elements: an identifier for the issuing authority (e.g. NCT, ISRCTN) plus a number.

Table3: Health condition tab

Tab name: HEALTH CONDITION **Description:** Characteristics of primary health conditions in the trial			
Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
HEALTH CONDITION	Primary health condition(s) or problem(s) studied	String	Studies can include more than one health condition

Table4: Condition code tab

Tab name: CONDITION CODE **Description:** Condition category and code of the trial, please see Data item definitions available on the ANZCTR for a full list of condition/code combinations.			
Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
CONDITION CATEGORY	The most appropriate condition category	String	Trials can include more than one category
Condition code	The most appropriate condition code	String	Trials can include more than one code

Table5: Intervention code tab

Tab name: INTERVENTION CODE **Description:** Characteristics of interventions of trials			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
INTERVENTION CODE	The most appropriate intervention code	Not applicable Diagnosis / prognosis Early detection / screening Prevention Treatment: drugs Treatment: surgery Treatment: devices Treatment: other Rehabilitation Lifestyle Behaviour	**Not applicable**: study in which no experimental intervention or treatment is applied. This selection is not available for interventional studies. **Diagnosis / prognosis**: study designed to evaluate one or more tests aimed at identifying a disease or health condition, or determining a patient's prognosis. **Early detection / screening**: study that involves the systematic examination of a group of participants, in order to separate well persons from those who have an undiagnosed pathologic condition or who are at high risk. It could also refer to the initial evaluation of an individual,

		Other interventions	intended to determine suitability for a particular treatment modality or to detect specific markers or characteristics that may require further investigation. **Prevention:** study designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition. **Treatment: drugs:** study designed to assess the effect(s) of one or more chemical or biological agents including vaccines. **Treatment: surgery:** study designed to assess the effect(s) of one or more manual or operative surgical techniques. **Treatment: devices:** study designed to evaluate the use of any physical item used in medical treatment whether it be an instrument, piece of equipment, machine, apparatus, appliance, material or other article. **Treatment: other:** studies that do not fall under the broad definitions of drug, surgical, or device trials. **Rehabilitation:** studies designed to evaluate one or more interventions which aim to restore the physical or mental health, function and quality of life in participants who have had or are currently suffering from an illness or injury. **Lifestyle**: studies designed to investigate the effect of interventions which relate to a way of life or style of living. Interventions may aim to alter the attitudes, habits and values of a person or group, and how these participants cope with their physical, psychological, social, and economic environments on a day-to-day basis. **Behaviour**: studies designed to assess the effect of interventions which aim to elicit or modify mental or

			physical actions, responses or conduct in a person or group. **Other interventions**: studies that do not fit under any of the above categories. This should only be selected when no other options are adequate. **Note:** Trials may include more than one intervention code

Table6: Outcome tab

Tab name: PRIMARY OUTCOME **Description:** Characteristics of the primary outcomes in the trials **Notes:** Trials can include maximum of 3 primary outcomes			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
OUTCOME	Primary outcome(s) is the outcome(s) which provides the primary measure of the effectiveness (or lack of effectiveness) of the intervention	String	
OUTCOME ASSESSMENT	The method of assessment used to assess the outcome. Note this field did not exist prior to September 2023.	String	
TIMEPOINT	All timepoints at which the primary outcome is assessed	String	

Table7: Secondary outcome tab

Tab name: SECONDARY OUTCOME **Description:** Characteristics of secondary outcomes of the trials **Notes:** Trials can include maximum of 40 secondary outcome and timepoints			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number

OUTCOME	Secondary outcomes are events, variables, or experiences that are of secondary interest or that are measured at timepoints of secondary interest.	String	
OUTCOME ASSESSMENT	The method of assessment used to assess the outcome. Note this field did not exist prior to September 2023.		
TIMEPOINT	All timepoints at which the secondary outcome is assessed	String	

Table8: Hospital tab

Tab name: HOSPITAL **Description:** information regarding the recruiting hospital of the trials **Notes:** Trials may include more than one hospital			
Variable name	Description	Values	Notes
TRIAL ID	Unique Trial ID	Integer	6-digit number
HOSPITAL	The full name of the recruiting sites (e.g. hospital and clinics)	String	

Table9: Postcode tab

Tab name: POSTCODE **Description:** information regarding the postcode where recruiting of the recruitment will occur inside Australia			
Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
POSTCODE	The four-digit postcode for the suburb where recruitment will occur	'4-digit postcode' – 'Suburb name'	

Table10: Country outside Australia tab

Tab name: COUNTRY OUTSIDE AUSTRALIA
Description: information regarding the country other than Australia in which recruitment with occur
Notes: Trials may include more than one country

Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
COUNTRY	Countries outside Australia	String	
STATE	State or province of that country	String	

Table11: Funding sources tab

Tab name: FUNDING SOURCE
Description: Information regarding funding sources of study
Notes: Trials may include up to 20 sets of entries

Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
FUNDING SOURCE TYPE	Major source(s) of monetary or material or infrastructure support for the study	Government body Hospital University Commercial sector/industry Charities/societies/foundations Other collaborative groups Self-funded/unfunded Other	The selection 'Self-funded/unfunded' applies to studies which are either funded by an individual person or not funded at all.
FUNDING SOURCE NAME	Name of funding source	String	
FUNDING SOURCE COUNTRY	Country of funding source	String	

Table12: Secondary sponsors tab

Tab name: SECONDARY SPONSOR **Description:** information regarding the secondary sources of the study **Notes:** Studies can include maximum of 20 secondary sponsors			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
SECONDARY SPONSOR TYPE	Type of secondary sponsor	Government body Hospital University Commercial sector/industry Charities/societies/foundations Other collaborative groups Other None	Additional individuals, organisations or other legal persons, that have agreed with the primary sponsor to jointly take on responsibilities of sponsorship.
SECONDARY SPONSOR NAME	Name of secondary sponsor	String	
SECONDARY SPONSOR COUNTRY	Country of secondary sponsor	String	

Table13: Other collaborators tab

Tab name: OTHER COLLABORATOR **Description:** information regarding other collaborators involved in the study **Notes:** Trial may include maximum of 20 other collaborators			
Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
OTHER COLLABORATOR TYPE	Additional individuals, organisations or other legal	Government body Hospital	

	persons, if any, that have agreed with the primary sponsor to jointly take on responsibilities of sponsorship	University Commercial sector/industry Charities/societies/foundations Other collaborative groups Other None	
OTHER COLLABORATOR NAME	Name of other collaborator	String	
OTHER COLLABORATOR COUNTRY	Country of other collaborator	String	

Table14: Ethics committees tab

Tab name: ETHICS COMMITTEE
Description: information regarding ethics committees approval
Notes: Trials may include a maximum of 50 entries

Variable name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
ETHICS COMMITTEE NAME	Name of ethics committee	String	
ETHICS COMMITTEE CONTACT DETAILS	Address or website of ethics committee	String	The website or full address of the ethics committee, including street number and name, suburb/town city, postcode and state/province
ETHICS COMMITTEE COUNTRY	Country of ethics committee	String	
ETHICS SUBMIT DATE	the date that the ethics committee application will be/ was submitted	dd/mm/yyyy	

ETHICS APPROVAL DATE	the date that the ethics committee application was approved.	dd/mm/yyyy	
HREC APPROVAL ID	The approval ID assigned to the ethics application by the ethics committee at the time of granting approval.	String	

Table15: Contacts tab

Tab name: CONTACTS **Description:** Contact detail of main contact of the trials			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
TYPE	Type of contact	Principal investigator Public Queries Scientific queries Updating information	**Note:** "Updating information" is no longer available and only belongs to old records
TITLE	Title of the contact	Ms Mrs Miss Mx Mr Dr A/Prof Prof	
NAME	Name of contact	String	
ADDRESS	Address of contact	String	Include work organisation/affiliation, street number and name,

			suburb/town city, postcode and state/province
COUNTRY	Country of contact	String	
PHONE	Phone number of contact	+country code, area code, number	
FAX	Fax number of contact	+country code, area code, number	
EMAIL	Email of contact	String	

Table16: Data sharing statement tab

Tab name: DATA SHARING STATEMENT **Description:** information regarding how and where the data will be shared **Note:** These fields did not exist prior to October 2018.			
Variables name	Description	Value	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
IPD AVAILABILITY	Indicates whether there is a plan to make individual participant data (IPD) publicly available for this trial	IPD and related data dictionaries are available IPD is not available Undecided	Due to new regulations **"Undecided"** option has been removed
DATA TO BE SHARED	Indicate what data will be shared	String	
TIMEFRAME	outlines the timeframe of data availability	String	
AVAILABLE TO WHOM?	Specifies who can/will be able to access the data	String	

FOR WHAT TYPES OF ANALYSES?	Indicates if there is a specific type of analysis for which the data are/will be available	String	
MECHANISIM	Specifies how/where data are/will be shared	String	
IPD COMMENTS	Other comments regarding the IPD	String	

Table17: Supporting documents tab

Tab name: SUPPORTING DOCUMENTS **Description:** provides details of how supporting documents are/will be available **Note:** These fields did not exist prior to October 2018.			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
TYPE	Type of supporting document that is/will be shared	Analytic code Clinical study report Data dictionary Ethical approval Informed consent form Statistical analysis plan Study protocol Other	
CITATION	Citation information for the supporting document	String	
LINK	A link where the study document can be found	String	
EMAIL	An email where requests for the study document can be made	String	

DETAILS	Other details for how the document is/will be available	String	
ATTACHMENT	A URL where the study document can be found	String	

Table18: Study results tab

Tab name: STUDY RESULTS **Description:** provides details of any study results and where they have been published. **Note:** These fields did not exist prior to October 2018, and list of options available in the 'Type' field were substantially expanded in May 2024.			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
TYPE	Indicates the type of study results available	Appendices Basic results Book Conference abstract Conference poster Funder report Interim results article Plain language summary Protocol Statistical analysis plan Study results article Supplementary materials Thesis Other files	
DOI	A Digital Object Identifier (DOI) link for where the results can be found	String	

CITATIONS OR OTHER DETAILS	A citation and/or other details for the study results	String	
ATTACHMENT	A URL where the results can be found	String	

Table19: External publications tab

Tab name: EXTERNAL PUBLICATIONS **Description:** provides details of study-related documents automatically identified using the study ACTRN in Embase or Dimensions AI. **Note: Data imports commenced in May 2024.**			
Variable name	Description	Values	Notes
TRIAL ID	Unique trial ID	Integer	6-digit number
SOURCE	Indicates the source for the study related document	Embase Dimensions AI	
DOI	A DOI link for where the publication can be found	String	
TITLE	The title of the publication	String	
YEAR OF PUBLICATION	The year of publication	YYYY	